Economic burden of the novel coronavirus infection: a systematic review

Background. The sudden emergence and rapid spread of the novel coronavirus infection (COVID-19) caused tremendous burden on the health care system including the economic one. In this regard, many questions concerning the prioritization of funding for various restrictive and preventive procedures have arisen; also the introduction of various intervention methods for monitoring and timely treatment of post-COVID consequences became an urgent problem. These challenges actualized the development of pharmacoeconomic methods that improve the quality of decisions making in such extreme conditions.

Objective: to systematize available studies on the assessment of the global economic burden of the novel coronavirus infection.

Material and methods. A feature of the proposed review design was the highlighting of the observed shortcomings and areas in which scientists make additions to the assessment methods taking into account the chronology of the pandemic determining changes in the information field. Therefore, an analysis was made of 80 studies published in 2020–2022 and dedicated to the assessment and forecast of the global economic burden of COVID-19. The main inclusion criteria for the studies was the estimation of COVID-19 global burden. The search was carried out in PubMed/MEDLINE, Web of Science, Scopus, and eLibrary databases. Using a predefined data collection form, two reviewers independently extracted information characterizing the studies.

Results. An analysis of the publications showed a fairly wide variety of studies in the field of the COVID-19 burden, including those determined by the difference in observation objects, analysis methods, factors taken into account, etc. Scientists actively use international (73.8%) and national (90%) databases, and surveys (57.5%). Predominantly, the estimates involve the calculation of quality-adjusted life years lost (QALY) (66.3%), 37.6% of the studies are based on the results of constructing scenario models, 28.8% consume algorithms of epidemiological SIR (susceptible, infected, or recovered) models, and 66.3% provide for cost assessment. As part of the estimated economic burden, the loss of productivity (26.3% of publications), the introduction of vaccination (32.5%), comorbidity (25%), post-COVID complications (17.5%) are considered.

Conclusion. A significant interest of the world scientific community in assessing the COVID-19 global burden is observed, determined by the search for the most effective study methods. Further investigations in this area should focus on detailing within the estimated economic burden of losses associated with post-COVID-19 complications, including their various combinations, as well as on the analysis of the correlation and mutual compensation of effects from various types of treatment, with a deeper study of indirect losses. The results of this work will be also useful in conducting similar studies, including for determining their design and applying modern mathematical modeling tools.

1. World Health Organization. Weekly epidemiological update on COVID-19 – 25 May 2022. 2022. Edition 93. Available at: https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19-25-may-2022 (accessed 30.05.2022).

2. Thom H., Walker J., Vickerman P., Hollingworth W. Exploratory comparison of Healthcare costs and benefits of the UK’s Covid-19 response with four European countries. Eur J Public Health. 2021; 31 (3): 619–24. https://doi.org/10.1093/eurpub/ckab019.

3. World Health Organization. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020: summary. Available at: https://apps.who.int/iris/handle/10665/41864 (accessed 30.05.2022).

4. Zeckhauser R., Shepard D. Where now for saving lives? Law and Contemporary Problems. 1976; 40 (4): 5–45. https://doi.org/10.2307/1191310.

5. Darovskikh A.А. The capabilities approach and health maximization: the challenges of the pandemic. Paradigm: Philosophical and Cultural Almanac. 2021; 34: 94–108.

6. da Silva R.C.L., Machado D.A., de Freitas Peregrino A.A., et al. Burden of SARS-CoV-2 infection among nursing professionals in Brazil. Rev Bras Enferm. 2021; 74 (Suppl. 1): e20200783. https://doi.org/10.1590/0034-7167-2020-0783.

7. Wouterse B., Ram F., van Baal P. Quality-adjusted life-years lost due to COVID-19 mortality: methods and application for the Netherlands. Value Health. 2022; 25 (5): 731–5. https://doi.org/10.1016/j.jval.2021.12.008.

8. Zafari Z., Goldman L., Kovrizhkin K., Muennig P.A. The cost-effectiveness of common strategies for the prevention of transmission of SARS-CoV-2 in universities. PLoS One. 2021; 16 (9): e0257806. https://doi.org/10.1371/journal.pone.0257806.

9. Losina E., Leifer V., Millham L., et al. College campuses and COVID-19 mitigation: clinical and economic value. Ann Intern Med. 2021; 174 (4): 472–83. https://doi.org/10.7326/M20-6558.

10. Bell D., Schultz Hansen K. Relative burdens of the COVID-19, malaria, tuberculosis, and HIV/AIDS epidemics in Sub-Saharan Africa. Am J Trop Med Hyg. 2021; 105 (6): 1510–5. https://doi.org/10.4269/ajtmh.21-0899.

11. Gheorghe A., Maringe C., Spice J., et al. Economic impact of avoidable cancer deaths caused by diagnostic delay during the COVID-19 pandemic: a national population-based modelling study in England, UK. Eur J Cancer. 2021; 152: 233–42. https://doi.org/10.1016/j.ejca.2021.04.019.

12. Galvain T., Patel S., Kabiri M., et al. Cost-effectiveness of bariatric and metabolic surgery, and implications of COVID-19 in the United Kingdom. Surg Obes Relat Dis. 2021; 17 (11): 1897–904. https://doi.org/10.1016/j.soard.2021.07.009.

13. Tsekhmister Y.V., Stepanenko V.I., Konovalova T., Tsekhmister B.V. Pharmaco economics analysis of COVID-19 vaccines in Ukraine. J Pharm Res Int. 2021; 33 (32A): 140–7. https://doi.org/10.9734/jpri/2021/v33i32A31727.

14. Congly S.E., Varughese R.A., Brown C.E., et al. Treatment of moderate to severe respiratory COVID-19: a cost-utility analysis. Sci Rep. 2021; 11: 17787. https://doi.org/10.1038/s41598-021-97259-7.

15. Padula W.V., Malaviya S., Reid N.M., et al. Economic value of vaccines to address the COVID-19 pandemic: a U.S. cost-effectiveness and budget impact analysis. J Med Econ. 2021; 24 (1): 1060–9. https://doi.org/10.1080/13696998.2021.1965732.

16. Kolbin A.S., Gomon Yu.M., Balykina Yu.E., et al. Socioeconomic and global burden of COVID-19. Kachestvennaya klinicheskaya praktika / Good Clinical Practice. 2021; 1: 24–34 (in Russ.). https://doi.org/10.37489/2588-0519-2021-1-24-34.

17. Wyper G.M.A., Assunção R., Cuschieri S., et al. Population vulnerability to COVID-19 in Europe: a burden of disease analysis. Arch Public Health. 2020; 78: 47. https://doi.org/10.1186/s13690-02000433-y.

18. Li R., Liu H., Fairley C.K., et al. Cost-effectiveness analysis of BNT162b2 COVID-19 booster vaccination in the United States. Int J Infect Dis. 2022; 119: 87–94. https://doi.org/10.1016/j.ijid.2022.03.029.

19. Oksuz E., Malhan S., Gonen M.S., et al. Cost-effectiveness analysis of remdesivir treatment in COVID-19 patients requiring low-flow oxygen therapy: payer perspective in Turkey. Adv Ther. 2021; 38 (9): 4935–48. https://doi.org/10.1007/s12325-021-01874-9.

20. Padula W.V., Miano M.A., Kelley M.A., et al. A cost-utility analysis of remote pulse-oximetry monitoring of patients with COVID-19. Value Health. 2022; 25 (6): 890–6. https://doi.org/10.1016/j.jval.2021.09.008.

21. He M., Li X., Tan Q., et al. Disease burden from COVID-19 symptoms among inpatients at the temporary military hospitals in Wuhan: a retrospective multicentre cross-sectional study. BMJ Open. 2021; 11 (5): e048822. https://doi.org/10.1136/bmjopen-2021-048822.

22. Fink G., Tediosi F., Felder S. Burden of Covid-19 restrictions: national, regional and global estimates. eClinicalMedicine. 2022; 45: 101305. https://doi.org/10.1016/j.eclinm.2022.101305.

23. Reif J., Heun-Johnson H., Tysinger B., et al. Measuring the COVID-19 mortality burden in the United States: a microsimulation study. Ann Intern Med. 2021; Sep 21: M21-2239. https://doi.org/10.7326/M21-2239.

24. Poteet S., Craig B.M. QALYs for COVID-19: a comparison of US EQ-5D-5L value sets. Patient. 2021; 14 (3): 339–45. https://doi.org/10.1007/s40271-021-00509-z.

25. Fernandes R.R.A., da Silva Santos M., da Silva Magliano C.A., et al. Cost utility of vaccination against COVID-19 in Brazil. Value Health Reg Issues. 2022; 31: 18–24. https://doi.org/10.1016/j.vhri.2022.01.009.

26. Gandjour A. Benefits, risks, and cost-effectiveness of COVID-19 self-tests from a consumer’s perspective. BMC Health Serv Res. 2022; 22 (1): 47. https://doi.org/10.1186/s12913-021-07277-4.

27. Cartocci A., Cevenini G., Barbini P. A compartment modeling approach to reconstruct and analyze gender and age-grouped CoViD-19 Italian data for decision – making strategies. J Biomed Inform. 2021; 118: 103793. https://doi.org/10.1016/j.jbi.2021.103793.

28. Packer C.H., Zhou C.G., Hersh A.R., et al. Antenatal corticosteroids for pregnant women at high risk of preterm delivery with COVID-19 infection: a decision analysis. Am J Perinatol. 2020; 37 (10): 1015–21. https://doi.org/10.1055/s-0040-1713145.

29. Rao I.J., Brandeau M.L. Optimal allocation of limited vaccine to control an infectious disease: simple analytical conditions. Math Biosci. 2021; 337: 108621. https://doi.org/10.1016/j.mbs.2021.108621.

30. Carta A., Conversano C. Cost utility analysis of Remdesivir and Dexamethasone treatment for hospitalised COVID-19 patients – a hypothetical study. BMC Health Serv Res. 2021; 21 (1): 986. https://doi.org/10.1186/s12913-021-06998-w.

31. John D., Narassima M.S., Menon J., et al. Estimation of the economic burden of COVID-19 using disability-adjusted life years (DALYs) and productivity losses in Kerala, India: a model-based analysis. BMJ Open. 2021; 11 (8): e049619. https://doi.org/10.1136/bmjopen-2021-049619.

32. Rommel A., von der Lippe E., Plass D., et al. The COVID-19 disease burden in Germany in 2020 – years of life lost to death and disease over the course of the pandemic. Dtsch Arztebl Int. 2021; 118 (9): 145–51. https://doi.org/10.3238/arztebl.m2021.0147.

33. Soodejani M.T., Gheshlaghi L.A., Bahrevar V., et al. Burden of severe COVID-19 in center of Iran: results of disability-adjusted life years (DALYs). Int J Mol Epidemiol Genet. 2021; 12 (6): 120–5.

34. Briggs A.H., Goldstein D.A., Kirwin E., et al. Estimating (quality-adjusted) life-year losses associated with deaths: with application to COVID-19. Health Econ. 2021; 30 (3): 699–707. https://doi.org/10.1002/hec.4208.

35. Asdaq S.M.B., Rabbani S.I., Alshammari M.K., et al. Burden of COVID-19: a preliminary analysis in the population of Saudi Arabia. Peer J. 2022; 10: e13219. https://doi.org/10.7717/peerj.13219.

36. Vasishtha G., Mohanty S.K., Mishra U.S., et al. Impact of COVID-19 infection on life expectancy, premature mortality, and DALY in Maharashtra, India. BMC Infect Dis. 2021; 21 (1): 343. https://doi.org/10.1186/s12879-021-06026-6.

37. Wyper G.M.A., Fletcher E., Grant I., et al. Inequalities in population health loss by multiple deprivation: COVID-19 and pre-pandemic all-cause disability-adjusted life years (DALYs) in Scotland. Int J Equity Health. 2021; 20 (1): 214. https://doi.org/10.1186/s12939-02101547-7.

38. Ilesanmi O.S., Afolabi A.A. Interrelationship between noncommunicable diseases, COVID-19, and sociodemographic index in the economic community of West African States. Int J Noncommun Dis. 2021; 6 (2): 77–83. https://doi.org/10.4103/jncd.jncd_16_21.

39. Gianino M.M., Savatteri A., Politano G., et al. Burden of COVID-19: disability-adjusted life years (DALYs) across 16 European countries. Eur Rev Med Pharmacol Sci. 2021; 25 (17): 5529–41. https://doi.org/10.26355/eurrev_202109_26665.

40. Miles D.K., Stedman M., Heald A.H. “Stay at home, protect the national health service, save lives”: a cost benefit analysis of the lockdown in the United Kingdom. Int J Clin Pract. 2021; 75 (3): e13674. https://doi.org/10.1111/ijcp.13674.

41. Oh I.H., Ock M., Jang S.Y., et al. Years of life lost attributable to COVID-19 in high-incidence countries. J Korean Med Sci. 2020; 35 (32): e300. https://doi.org/10.3346/jkms.2020.35.e300.

42. Uskoković V. Nanomedicine for the poor: a lost cause or an idea whose time has yet to come? Nanomedicine (Lond). 2021; 16 (14): 1203–18. https://doi.org/10.2217/nnm-2021-0024.

43. Wyper G.M.A., Fletcher E., Grant I., et al. Measuring disability-adjusted life years (DALYs) due to COVID-19 in Scotland, 2020. Arch Public Health. 2022; 80: 105. https://doi.org/10.1186/s13690-022-00862-x.

44. Cuschieri S., Calleja N., Devleesschauwer B., et al. Estimating the direct Covid-19 disability-adjusted life years impact on the Malta population for the first full year. BMC Public Health. 2021; 21 (1): 1827. https://doi.org/10.1186/s12889-021-11893-4.

45. Chapman L.A.C., Shukla P., Rodríguez-Barraquer I., et al. Risk factor targeting for vaccine prioritization during the COVID-19 pandemic. Sci Rep. 2022; 12 (1): 3055. https://doi.org/10.1038/s41598-02206971-5.

46. Lally M. A cost-benefit analysis of COVID-19 lockdowns in Australia. Monash Bioeth Rev. 2022; Jan 28: 1–32. https://doi.org/10.1007/s40592-021-00148-y.

47. Bagepally B.S., Haridoss M., Natarajan M., et al. Cost-effectiveness of surgical mask, N-95 respirator, hand-hygiene and surgical mask with hand hygiene in the prevention of COVID-19: cost effectiveness analysis from Indian context. Clin Epidemiol Glob Health. 2021; 10: 100702. https://doi.org/10.1016/j.cegh.2021.100702.

48. Acuña-Zegarra M.A., Díaz-Infante S., Baca-Carrasco D., Olmos-Liceaga D. COVID-19 optimal vaccination policies: a modeling study on efficacy, natural and vaccine-induced immunity responses. Math Biosci. 2021; 337: 108614. https://doi.org/10.1016/j.mbs.2021.108614.

49. Jiang Y., Cai D., Chen D., et al. Economic evaluation of remdesivir for the treatment of severe COVID-19 patients in China under different scenarios. Br J Clin Pharmacol. 2021; 87 (11): 4386–96. https://doi.org/10.1111/bcp.14860.

50. Ohsfeldt R., Kelton K., Klein T., et al. Cost-effectiveness of baricitinib compared with standard of care: a modeling study in hospitalized patients with COVID-19 in the United States. Clin Therapeut. 2021; 43 (11): 1877–93.e4. https://doi.org/10.1016/j.clinthera.2021.09.016.

51. Vordos N., Gkika D. A., Maliaris G., et al. How 3D printing and social media tackles the PPE shortage during Covid-19 pandemic. Saf Sci. 2020; 130: 104870. https://doi.org/10.1016/j.ssci.2020.104870.

52. Jo M.W., Go D.S., Kim R., et al. The burden of disease due to COVID-19 in Korea using disability-adjusted life years. J Korean Med Sci. 2020; 35 (21): e199. https://doi.org/10.3346/jkms.2020.35.e199.

53. Zhou C.G., Packer C.H., Hersh A.R., Caughey A.B. Antenatal corticosteroids for pregnant women with COVID-19 infection and preterm prelabor rupture of membranes: a decision analysis. J Matern Fetal Neonatal Med. 2022; 35 (9): 1643–51. https://doi.org/10.1080/14767058.2020.1763951.

54. Yanev I., Gagnon M., Cheng M.P., et al. Kidney transplantation in times of Covid-19: decision analysis in the Canadian context. Can J Kidney Health Dis. 2021; 8: 20543581211040332. https://doi.org/10.1177/20543581211040332.

55. Singh B.B., Devleesschauwer B., Khatkar M.S., et al. Disability-adjusted life years (DALYs) due to the direct health impact of COVID-19 in India, 2020. Sci Rep. 2022; 12 (1): 2454. https://doi.org/10.1038/s41598-022-06505-z.

56. Jiang Y., Cai D., Chen D., et al. The cost-effectiveness of conducting three versus two reverse transcription-polymerase chain reaction tests for diagnosing and discharging people with COVID-19: evidence from the epidemic in Wuhan, China. BMJ Glob Health. 2020; 5: e002690. https://doi.org/10.1136/bmjgh-2020-002690.

57. Grover G., Magan R. Estimation of quality adjusted life year (QALY) for different states of india during COVID-19. Statistics and Applications. 2020; 18 (1): 319–31.

58. Nurchis M.C., Pascucci D., Sapienza M., et al. Impact of the burden of COVID-19 in Italy: results of disability-adjusted life years (DALYs) and productivity loss. Int J Environ Res Public Health. 2020; 17 (12): 4233. https://doi.org/10.3390/ijerph17124233.

59. Schonberger R.B., Listokin Y.J., Ayres I., et al. Cost benefit analysis of limited reopening relative to a herd immunity strategy or shelter in place for SARS-CoV-2 in the United States. medRxiv. 2020. https://doi.org/10.1101/2020.06.26.20141044.

60. Dijk S.W., Krijkamp E.M., Kunst N., et al. Emerging therapies for COVID-19: the value of information from more clinical trials. Value Health. 2022; Apr 27: S1098-3015(22)00158-9. https://doi.org/10.1016/j.jval.2022.03.016.

61. Vaezi A., Meysamie A. COVID-19 vaccines cost-effectiveness analysis: a scenario for Iran. Vaccines (Basel). 2022; 10 (1): 37. https://doi.org/10.3390/vaccines10010037.

62. Xiong X., Li J., Huang B., et al. Economic value of vaccines to address the COVID-19 pandemic in Hong Kong: a cost-effectiveness analysis. Vaccines (Basel). 2022; 10 (4): 495. https://doi.org/10.3390/vaccines10040495.

63. Whittington M.D., Pearson S.D., Rind D.M., Campbell J.D. The cost-effectiveness of remdesivir for hospitalized patients with COVID-19. Value Health. 2022; 25 (5): 744–50. https://doi.org/10.1016/j.jval.2021.11.1378.

64. Rafia R., Martyn-St James M., Harnan S., et al. A cost-effectiveness analysis of remdesivir for the treatment of hospitalized patients with COVID-19 in England and Wales. Value Health. 2022; 25 (5): 761–9. https://doi.org/10.1016/j.jval.2021.12.015.

65. Bartsch S.M., Wedlock P.T., O’Shea K.J., et al. Lives and costs saved by expanding and expediting coronavirus disease 2019 vaccination. J Infect Dis. 2021; 224 (6): 938–48. https://doi.org/10.1093/infdis/jiab233.

66. Kohli M., Maschio M., Becker D., Weinstein M.C. The potential public health and economic value of a hypothetical COVID-19 vaccine in the United States: use of cost-effectiveness modeling to inform vaccination prioritization. Vaccine. 2021; 39 (7): 1157–64. https://doi.org/10.1016/j.vaccine.2020.12.078.

67. Miles D.K., Heald A.H., Stedman M. How fast should social restrictions be eased in England as COVID-19 vaccinations are rolled out? Int J Clin Pract. 2021; 75 (7): e14191. https://doi.org/10.1111/ijcp.14191.

68. Shimul S.N., Alradie-Mohamed A., Kabir R., et al. Effect of easing lockdown and restriction measures on COVID-19 epidemic projection: a case study of Saudi Arabia. PLoS One. 2021; 16 (9): e0256958. https://doi.org/10.1371/journal.pone.0256958.

69. Sandmann F.G., Davies N.G., Vassall A., et al. The potential health and economic value of SARS-CoV-2 vaccination alongside physical distancing in the UK: a transmission model-based future scenario analysis and economic evaluation. Lancet Infect Dis. 2021; 21 (7): 962–74. https://doi.org/10.1016/S1473-3099(21)00079-7.

70. Moore S., Hill E.M., Dyson L., et al. Modelling optimal vaccination strategy for SARS-CoV-2 in the UK. PLoS Comput Biol. 2021; 17 (5): e1008849. https://doi.org/10.1371/journal.pcbi.1008849.

71. Debrabant K., Grønbæk L., Kronborg C. The cost-effectiveness of a COVID-19 vaccine in a Danish context. Clin Drug Investig. 2021; 41 (11): 975–88. https://doi.org/10.1007/s40261-021-01085-8.

72. Basu A., Gandhay V.J. Quality-adjusted life-year losses averted with every COVID-19 infection prevented in the United States. Value Health. 2021; 24 (5): 632–40. https://doi.org/10.1016/j.jval.2020.11.013.

73. Zhao J., Jin H., Li X., et al. Disease burden attributable to the first wave of COVID-19 in China and the effect of timing on the cost-effectiveness of movement restriction policies. Value Health. 2021; 24 (5): 615–24. https://doi.org/10.1016/j.jval.2020.12.009.

74. Kelton K., Klein T., Murphy D., et al. Cost-effectiveness of combination of baricitinib and remdesivir in hospitalized patients with COVID-19 in the United States: a modelling study. Adv Ther. 2022; 39 (1): 562–82. https://doi.org/10.1007/s12325-021-01982-6.

75. Hagens A., İnkaya A.Ç., Yildirak K., et al. COVID-19 vaccination scenarios: a cost-effectiveness analysis for Turkey. Vaccines (Basel). 2021; 9 (4): 399. https://doi.org/10.3390/vaccines9040399.

76. Pearson C.A.B., Bozzani F., Procter S.R., et al. COVID-19 vaccination in Sindh Province, Pakistan: a modelling study of health impact and costeffectiveness. PLoS Med. 2021; 18 (10): e1003815. https://doi.org/10.1371/journal.pmed.1003815.

77. Neilan A.M., Losina E., Bangs A.C., et al. Clinical impact, costs, and cost-effectiveness of expanded severe acute respiratory syndrome coronavirus 2 testing in Massachusetts. Clin Infect Dis. 2021; 73 (9): e2908–17. https://doi.org/10.1093/cid/ciaa1418.

78. Cleary S.M., Wilkinson T., Tamandjou Tchuem C.R., et al. Cost-effectiveness of intensive care for hospitalized COVID-19 patients: experience from South Africa. BMC Health Serv Res. 2021; 21 (1): 82. https://doi.org/10.1186/s12913-021-06081-4.

79. Zala D., Mosweu I., Critchlow S., et al. Costing the COVID-19 pandemic: an exploratory economic evaluation of hypothetical suppression policy in the United Kingdom. Value Health. 2020; 23 (11): 1432–7. https://doi.org/10.1016/j.jval.2020.07.001.

80. Marco-Franco J.E., Pita-Barros P., González-de-Julián S., et al. Simplified mathematical modeling of uncertainty: cost-effectiveness of COVID-19 vaccines in Spain. Mathematics. 2021; 9 (5): 566. https://doi.org/10.3390/math9050566.

81. Angeles M.R., Wanni Arachchige Dona S., Nguyen H., et al. Modelling the potential acute and post-acute burden of COVID-19 under the Australian border re-opening plan. BMC Public Health. 2022; 22 (1): 757. https://doi.org/10.1186/s12889-022-13169-x.

82. Sinha P., Linas B.P. Combination therapy with tocilizumab and dexamethasone cost-effectively reduces coronavirus disease 2019 mortality. Clin Infect Dis. 2021; 73 (11): 2116–8. https://doi.org/10.1093/cid/ciab409.

83. Martin C., Luteijn M., Letton W., et al. A model framework for projecting the prevalence and impact of long-COVID in the UK. PLoS One. 2021; 16 (12): e0260843. https://doi.org/10.1371/journal.pone.0260843.

84. Smith M.P. Estimating total morbidity burden of COVID-19: relative importance of death and disability. J Clin Epidemiol. 2022; 142: 54–9. https://doi.org/10.1016/j.jclinepi.2021.10.018.

85. van der Pol S., Garcia P.R., Postma M.J., et al. Economic analyses of respiratory tract infection diagnostics: a systematic review. Pharmacoeconomics. 2021; 39 (12): 1411–27. https://doi.org/10.1007/s40273021-01054-1.

86. Podolsky M.I., Present I., Neumann P.J., Kim D.D. A systematic review of economic evaluations of COVID-19 interventions: considerations of non-health impacts and distributional issues. Value Health. 2022; Apr 6: S1098-3015(22)00102-4. https://doi.org/10.1016/j.jval.2022.02.003.